Catabasis and Sarepta join forces to explore drug combo for Duchenne muscular dystrophy

1 October 2016
2019_biotech_test_vial_discovery_big

Hot on the heels of finally gaining US Food and Drug Administration approval for its Exondys 51 (eteplirsen), US biotech Sarepta Therapeutics (Nasdaq: SRPT) had entered into a research collaboration with clinical-stage biopharma company Catabasis (Nasdaq: CATB) to explore a combination drug treatment approach for Duchenne muscular dystrophy (DMD).

The two companies will contribute their respective expertise to study an exon-on-skippingskipping treatment developed by Sarepta, together with an oral NF-kB inhibition treatment developed by Catabasis in a mouse model of DMD.

Even though no financial terms were disclosed, news of the collaboration sent Catabasis’ shares rocketing as much as 58% to $7.02, their highest point since June, as the company’s chief executive noted that

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology